Published in Nucleic Acids Res on July 08, 2010
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther (2011) 1.23
Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med (2013) 1.21
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res (2014) 1.18
Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids (2013) 1.10
Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther (2011) 1.03
TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res (2012) 1.03
A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther (2013) 1.00
Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol Ther (2011) 0.96
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther (2013) 0.91
Oligonucleotide conjugates for therapeutic applications. Ther Deliv (2013) 0.89
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res (2015) 0.88
Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res (2013) 0.87
Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artif DNA PNA XNA (2012) 0.87
Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Mol Ther Nucleic Acids (2012) 0.86
Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids (2012) 0.86
Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther (2013) 0.86
A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids (2014) 0.84
In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res (2015) 0.84
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem (2014) 0.84
Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors. J Nucleic Acids (2012) 0.83
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun (2015) 0.81
In vitro selection of BNA (LNA) aptamers. Artif DNA PNA XNA (2013) 0.81
Insights from crystal structures into the opposite effects on RNA affinity caused by the S- and R-6'-methyl backbone modifications of 3'-fluoro hexitol nucleic acid. Biochemistry (2011) 0.81
Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice. Nucleic Acid Ther (2014) 0.81
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest (2014) 0.80
Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol. Mol Ther Nucleic Acids (2015) 0.79
Synthesis and biophysical properties of C5-functionalized LNA (locked nucleic acid). J Org Chem (2014) 0.78
Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res (2014) 0.78
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. Mol Ther Nucleic Acids (2016) 0.78
Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells. Nucleic Acids Res (2014) 0.78
C5-alkynyl-functionalized α-L-LNA: synthesis, thermal denaturation experiments and enzymatic stability. J Org Chem (2014) 0.78
The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol (2017) 0.77
Establishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide Drugs. PLoS One (2016) 0.77
Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. Mol Ther Nucleic Acids (2014) 0.77
Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes. BMC Genomics (2015) 0.77
Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice. Br J Pharmacol (2012) 0.76
Development of Antisense Drugs for Dyslipidemia. J Atheroscler Thromb (2016) 0.76
Ca2+ enrichment in culture medium potentiates effect of oligonucleotides. Nucleic Acids Res (2015) 0.75
Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Res (2017) 0.75
Functional correction by antisense therapy of a splicing mutation in the GALT gene. Eur J Hum Genet (2014) 0.75
Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers. Nucleic Acids Res (2015) 0.75
Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy. Mol Ther Nucleic Acids (2016) 0.75
GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells. Sci Rep (2016) 0.75
Quantum mechanical studies of DNA and LNA. Nucleic Acid Ther (2014) 0.75
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides. Sci Rep (2016) 0.75
Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res (2014) 0.75
From the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides. Toxicol Sci (2017) 0.75
Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes. PLoS One (2017) 0.75
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res (2002) 2.58
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation (2006) 2.08
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res (2002) 1.97
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res (2005) 1.96
Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res (1993) 1.93
Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem (2009) 1.61
Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther (2008) 1.59
Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res (2002) 1.52
Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol (1992) 1.52
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res (2003) 1.42
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol (2008) 1.42
Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs (2007) 1.20
Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry (2002) 1.19
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag (2007) 1.15
Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res (2003) 1.10
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides (2006) 1.09
Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides (2006) 1.08
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet (2009) 1.02
Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids (2003) 0.99
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem (2005) 0.97
Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol (2007) 0.94
Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. FEBS Lett (2004) 0.92
Expression of apolipoprotein B in the kidney attenuates renal lipid accumulation. J Biol Chem (2010) 0.92
Reduction of lipocalin-type prostaglandin D synthase in the preoptic area of female mice mimics estradiol effects on arousal and sex behavior. Proc Natl Acad Sci U S A (2003) 0.90
A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides (2004) 0.89
Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides (2004) 0.81
Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions. J Clin Endocrinol Metab (2004) 0.81
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX (2009) 1.97
Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res (2009) 1.72
The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol (2006) 1.57
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther (2008) 1.49
Caesarean section and hospitalization for respiratory syncytial virus infection: a population-based study. Pediatr Infect Dis J (2015) 1.44
Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther (2006) 1.42
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther (2011) 1.23
Galectin-3 contributes to neonatal hypoxic-ischemic brain injury. Neurobiol Dis (2010) 1.21
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One (2010) 1.19
An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther (2008) 1.15
SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther (2008) 1.15
IGF-I neuroprotection in the immature brain after hypoxia-ischemia, involvement of Akt and GSK3beta? Eur J Neurosci (2005) 1.12
A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther (2012) 1.12
Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res (2003) 1.10
Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids (2003) 0.99
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem (2005) 0.97
Locked nucleic acid synthesis. Methods Mol Biol (2005) 0.96
Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol Biol (2012) 0.96
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer (2011) 0.95
Perilipin and adipophilin expression in lipid loaded macrophages. Biochem Biophys Res Commun (2007) 0.94
Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells. BMC Immunol (2008) 0.94
Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet (2013) 0.93
Effect of lipopolysaccharide on global gene expression in the immature rat brain. Pediatr Res (2006) 0.92
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther (2013) 0.91
Cytokine response to lipoprotein lipid loading in human monocyte-derived macrophages. Lipids Health Dis (2006) 0.91
The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica (2013) 0.90
Very low-density lipoprotein induces interleukin-1beta expression in macrophages. Biochem Biophys Res Commun (2005) 0.86
Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine (2004) 0.86
Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark. Scand J Infect Dis (2007) 0.86
Lack of nonfunctional B-cell receptor rearrangements in a patient with normal B cell numbers despite partial RAG1 deficiency and atypical SCID/Omenn syndrome. J Clin Immunol (2008) 0.86
Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs (2011) 0.85
LNA guanine and 2,6-diaminopurine. Synthesis, characterization and hybridization properties of LNA 2,6-diaminopurine containing oligonucleotides. Bioorg Med Chem (2004) 0.84
Elastin and calcium rather than collagen or lipid content are associated with echogenicity of human carotid plaques. Stroke (2004) 0.83
Locked nucleic acid holds promise in the treatment of cancer. Curr Pharm Des (2008) 0.81
Immunodeficiency associated with a nonsense mutation of IKBKB. J Clin Immunol (2014) 0.81
Disruption of interleukin-18, but not interleukin-1, increases vulnerability to preterm delivery and fetal mortality after intrauterine inflammation. Am J Pathol (2006) 0.81
Effects of oats on plasma cholesterol and lipoproteins in C57BL/6 mice are substrain specific. Br J Nutr (2009) 0.81
The possibility of discriminating within the Bacillus cereus group using gyrB sequencing and PCR-RFLP. Int J Food Microbiol (2005) 0.80
[Prevention of vertical transmission of HIV in Denmark]. Ugeskr Laeger (2008) 0.80
Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids (2007) 0.80
Autoimmune responses against the apo B-100 LDL receptor-binding site protect against arterial accumulation of lipids in LDL receptor deficient mice. Autoimmunity (2007) 0.79
Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis. Am J Pathol (2010) 0.79
Evaluation of LNA-modified DNAzymes targeting a single nucleotide polymorphism in the large subunit of RNA polymerase II. Oligonucleotides (2005) 0.79
Design, synthesis, and biological evaluation of LNA nucleosides as adenosine A3 receptor ligands. Bioorg Med Chem (2007) 0.79
Synthesis of 2'-amino-LNA: a new strategy. Org Biomol Chem (2003) 0.78
Locked nucleic acid aptamers. Methods Mol Biol (2009) 0.78
GB virus C epidemiology in Denmark: different routes of transmission in children and low- and high-risk adults. J Med Virol (2003) 0.77
Assessment of carcinogenicity of di(2-ethylhexyl)phthalate in a short-term assay using Xpa-/- and Xpa-/-/p53+/- mice. Toxicol Pathol (2002) 0.77
The burden of rotavirus disease in Denmark 2009-2010. Pediatr Infect Dis J (2011) 0.77
Infant Respiratory Tract Infections or Wheeze and Maternal Vitamin D in Pregnancy: A Systematic Review. Pediatr Infect Dis J (2016) 0.76
Role of mixed lineage kinase inhibition in neonatal hypoxia-ischemia. Dev Neurosci (2009) 0.76
Synthesis and biological evaluation of LNA phosphoramidates. Nucleosides Nucleotides Nucleic Acids (2008) 0.76
CD4+ CD31+ recent thymic emigrants in CHD7 haploinsufficiency (CHARGE syndrome): a case. Hum Immunol (2013) 0.75
Quantum mechanical studies of DNA and LNA. Nucleic Acid Ther (2014) 0.75
Medial Expression of TNF-α and TNF Receptors Precedes the Development of Atherosclerotic Lesions in Apolipoprotein E/LDL Receptor Double Knockout Mice. Int J Biomed Sci (2007) 0.75
Hospitalisation with otitis media in early childhood and cognitive function in young adult life: a prevalence study among Danish conscripts. BMC Pediatr (2013) 0.75
Infantile hemophagocytic lymphohistiocytosis in a case of chediak-higashi syndrome caused by a mutation in the LYST/CHS1 gene presenting with delayed umbilical cord detachment and diarrhea. J Pediatr Hematol Oncol (2015) 0.75
No serological evidence for rickettsial diseases among Danish elite orienteerers. Ann N Y Acad Sci (2006) 0.75
Synthesis of 2'-amino-LNA purine nucleosides. Nucleosides Nucleotides Nucleic Acids (2006) 0.75
Improved synthesis of 2'-amino-LNA. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
Health-related quality of life in Danish children with hereditary angioedema. Allergy Asthma Proc (2017) 0.75
New standards in LNA synthesis. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
Association Between Mode of Delivery and Risk of Infection in Early Childhood: A Cohort Study. Pediatr Infect Dis J (2017) 0.75
Low seroprevalence of bartonella species in danish elite orienteers. Scand J Infect Dis (2004) 0.75
Activator protein-1 in carotid plaques is related to cerebrovascular symptoms and cholesteryl ester content. Cardiovasc Pathol (2010) 0.75